In a welcome move, CG Oncology saw its Relative Strength Rating improve from 67 to 74 on Tuesday.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's unique RS Rating tracks technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the best stocks often have an RS Rating of above 80 as they launch their largest price moves. See if CG Oncology can continue to show renewed price strength and hit that benchmark.
CG Oncology is within a buy range after breaking past a 32.30 buy point in a consolidation. The proper buying range extends to 5% above the initial entry. Once a stock moves above that range, it's best to wait for it to set up another buying opportunity..
The company reported 0% EPS growth in its most recent report, while sales growth came in at -100%.
The company holds the No. 193 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
